Logo do repositório
 
Publicação

Vaccine effectiveness against medically attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25

2026-03-17Artigo científico Acesso aberto
Ver registo simples
datacite.subject.fosCiências Médicas::Ciências da Saúde
datacite.subject.sdg03:Saúde de Qualidade
dc.contributor.authorLucaccioni, Héloïse
dc.contributor.authorPozo, Francisco
dc.contributor.authorPérez-Gimeno, Gloria
dc.contributor.authorDürrwald, Ralf
dc.contributor.authorUras, Marina
dc.contributor.authorDomegan, Lisa
dc.contributor.authorOroszi, Beatrix
dc.contributor.authorMeijer, Adam
dc.contributor.authorTrobajo-Sanmartín, Camino
dc.contributor.authorUjvari, Dorina
dc.contributor.authorRodrigues, Ana Paula
dc.contributor.authorMlinarić, Ivan
dc.contributor.authorLazar, Mihaela
dc.contributor.authorRivas Wagner, Eva
dc.contributor.authorErdwiens, Annika
dc.contributor.authorEnouf, Vincent
dc.contributor.authorMcKenna, Adele
dc.contributor.authorTúri, Gergő
dc.contributor.authorde Lange, Marit
dc.contributor.authorMartínez-Baz, Iván
dc.contributor.authorLatorre-Margalef, Neus
dc.contributor.authorGuiomar, Raquel
dc.contributor.authorKurečić Filipovic, Sanja
dc.contributor.authorDinu, Sorin
dc.contributor.authorMokoroa, Olatz
dc.contributor.authorTolksdorf, Kristin
dc.contributor.authorMasse, Shirley
dc.contributor.authorBennett, Charlene
dc.contributor.authorKristóf, Katalin
dc.contributor.authorHooiveld, Mariette
dc.contributor.authorCastilla, Jesús
dc.contributor.authorSantos Almeida, João
dc.contributor.authorVišekruna Vučina, Vesna
dc.contributor.authorPopescu, Rodica
dc.contributor.authorBacci, Sabrina
dc.contributor.authorKaczmarek, Marlena
dc.contributor.authorKissling, Esther
dc.date.accessioned2026-09-28T14:59:35Z
dc.date.available2026-09-28T14:59:35Z
dc.date.issued2026-03-17
dc.descriptionI-MOVE primary care network in Europe - VEBIS project: Ausenda Machado, Licínia Gomes, Daniela Dias, Camila Henriques, Nuno Verdasca (INSA).
dc.description.abstractBackground: We conducted a multicenter test-negative study to estimate vaccine effectiveness (VE) against medically attended, laboratory-confirmed influenza in primary care, Europe, 2024/25. Research design and methods: Specimens were collected from patients with acute respiratory infection. All or a random sample of viruses were sequenced. VE was (1-odds ratio) × 100, adjusted for confounders. Results: We included 7275 cases and 17,516 controls (weeks 40-2024-18-2025). The overall VE was 46% (95% CI: 40-52), lowest in adults ≥65 years at 28% (95% CI: 12-42). VE against influenza A(H1N1)pdm09 was 30% (95% CI: 19-40); ranging 16-34% by age and vaccination target group. Most (88%) circulating clades were 5a.2a, distinct from the vaccine clade. VE was 28% (95% CI: 7-45) against 5a.2a (C.1.9), and 6% (95% CI: -62-45) against the vaccine-matched clade 5a.2a.1 (D). VE against influenza A(H3N2) was 38% (95% CI: 26-49); ranging 20-66% by age and target group. Circulating viruses belonged to the vaccine clade 2a.3a.1, with 88% subclade (J.2). VE against influenza B was 76% (95% CI: 69-81); ranging 70-80% by age and target group; all viruses belonged to the vaccine clade V1A.3a.2, with diverse subclades. Conclusions: Influenza vaccination protected approximately one in two vaccinated individuals against medically attended infection in primary care in Europe, 2024/25, varying by (sub)type and age.eng
dc.description.sponsorshipThis manuscript was funded by the European Centre for Disease Prevention and Control under the framework contract [ECDC/2021/019].
dc.identifier.citationExpert Rev Vaccines. 2026 Dec;25(1):2645378. doi: 10.1080/14760584.2026.2645378. Epub 2026 Mar 17
dc.identifier.doi10.1080/14760584.2026.2645378
dc.identifier.eissn1744-8395
dc.identifier.issn1476-0584
dc.identifier.pmid41816931
dc.identifier.urihttp://hdl.handle.net/10400.18/11347
dc.language.isoeng
dc.peerreviewedyes
dc.publisherTaylor and Francis Group
dc.relation.hasversionhttps://www.tandfonline.com/doi/10.1080/14760584.2026.2645378?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed#abstract
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectCase Control Study
dc.subjectInfluenza
dc.subjectInfluenza Vaccine
dc.subjectMulticenter Study
dc.subjectObservational Study
dc.subjectTest-Negative Design
dc.subjectVaccine Effectiveness
dc.subjectVEBIS
dc.subjectEurope
dc.subjectCuidados de Saúde
dc.subjectInfecções Respiratórias
dc.titleVaccine effectiveness against medically attended, laboratory-confirmed influenza in the I-MOVE primary care network in Europe, VEBIS project, 2024/25eng
dc.typejournal article
dcterms.referenceshttps://www.tandfonline.com/doi/suppl/10.1080/14760584.2026.2645378?scroll=top
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.startPage2645378
oaire.citation.titleExpert Review of Vaccines
oaire.citation.volume25
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Lucaccioni_2026_Vaccine effectiveness against medically-attended lab-confirmed influenza I-MOVE PC 2024 25.pdf
Tamanho:
2.33 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DEP - Artigos em revistas internacionais
DDI - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais